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Abstract 
Background. The aim was to establish the features of hemodynamic and metabolic 
parameters in obese patients with true and pseudo-resistant arterial hypertension (AH). 
Material and methods. The study included 200 patients with uncontrolled AH and obesity. 
Patients were initially prescribed dual antihypertensive therapy. Those patients who did not 
reach target blood pressure (BP) levels after 3 months on dual therapy were additionally 
prescribed a third antihypertensive drug. Of the 98 patients who were assigned to triple 
therapy, 48 patients did not reach target BP (27 patients had pseudo-resistant and 21 patients 
had true resistant AH). These patients were additionally prescribed a fourth antihypertensive 
drug (spironolactone). The effectiveness of the treatment was evaluated 6 months after the 
start of antihypertensive therapy. 
Results: After 6 months of therapy, unlike patients without resistance, individuals with 
resistant AH had more pronounced cardiovascular remodeling and metabolic disorders, 
disbalance of oxidative stress-antioxidant protection, proinflammatory activity and higher 
activity of the renin-angiotensin-aldosterone system. Patients with true resistance differed 
from pseudo-resistant patients by having significantly lower body mass index (BMI); in the 
absence of differences in BP levels, cardiovascular remodeling, lipid and carbohydrate 
profiles, patients with true resistance had significantly higher levels of aldosterone, higher 
activity of oxidative stress system, lower levels of general antioxidant protection, higher 
adiponectin levels, and lower leptin level. 
Conclusions: Obese patients with true resistance differed from pseudo-resistant patients by 
having significantly lower BMI, higher aldosterone levels, more pronounced imbalance of the 
system of oxidative stress-antioxidant protection and less pronounced adipokine imbalance. 
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Introduction 
Resistant hypertension (RH) is an important cause of cardiovascular morbidity and 
mortality. According to the definition of resistance presented in the 2018 ESC/ESH 
Guidelines for the management of arterial hypertension (AH), RH should be diagnosed when 
the recommended treatment strategy fails to lower office systolic and diastolic blood pressure 
(SBP and DBP) values to less than 140 mm Hg and/or less than 90 mm Hg, respectively, and 
the inadequate control of BP is confirmed by ambulatory or home BP monitoring in patients 
whose adherence to therapy has been confirmed [1]. As indicated in the specified Guidelines, 
the treatment strategy should include appropriate lifestyle measures and treatment with 
optimal or best tolerated doses of three or more drugs, which should include a diuretic, 
typically an angiotensin-converting enzyme (ACE) inhibitor (or an angiotensin II receptor 
blockers) and a calcium channel blockers (CCB) [1]. 
At the same time, pseudo-resistant hypertension (due to low compliance with 
treatment, the white-coat phenomenon, increased calcification of the shoulder arteries and a 
number of other causes) and true resistance should be distinguished. Both true and pseudo-
resistant hypertensions represent a big problem not only in BP control, but also in those 
possible adverse cardiovascular events, the development of which is associated with failure to 
achieve target BP levels. 
Resistant hypertension patients require a multimodal approach to control BP. In most 
patients, RH can be influenced by optimizing combination antihypertensive therapy to 
improve compliance and lifestyle correction [1, 2]. As indicated in the 2018 ESC/ESH 
Guidelines [1], in the case of RH, an antagonist of mineralocorticoid receptors should be 
additionally prescribed to patients, due to its effect on a number of pathogenetic mechanisms 
such as the suppression of macrophage infiltration and improvement of endothelium-
dependent vasodilatation (EDVD) [3–6]. There is evidence of a more pronounced hypotensive 
effect of aldosterone blockers in patients with increased waist circumference than in patients 
with its normal values [7–9]. 
Given the high prevalence of comorbidity of AH and obesity on the one hand and a 
large percentage of people with insufficiently controlled AH on the other hand, the study of 
the features of true resistance and pseudo-resistance in obese patients deserves attention. 
The aim of the study was to establish the features of hemodynamic and metabolic 
parameters in obese patients with true and pseudo-resistant AH. 
 
Material and methods 
The study included 200 patients with uncontrolled AH and obesity classes I–II (the age 45–55 
years). Antihypertensive therapy was prescribed in accordance with the 2018 ESC/ESH 
Guidelines for the management of AH [1]. Dual antihypertensive therapy (ACE inhibitor and 
CCB) was administered to patients first. Those patients who did not reach the target BP levels 
of dual therapy after 3 months were further prescribed a third antihypertensive drug (the 
thiazide-like diuretic indapamide). Of the 98 patients who were assigned to triple therapy, 48 
patients did not reach the target BP levels: 27 patients had pseudo-resistant hypertension (due 
to low compliance with treatment and insufficient adherence to the physician's instructions to 
ensure adequate levels of physical activity), and 21 patients had true RH (did not achieve 
target BP levels with triple antihypertensive therapy and sufficient physical activity). These 
patients were additionally prescribed a fourth antihypertensive drug — spironolactone. The 
effectiveness of the treatment was evaluated 6 months after the start of antihypertensive 
therapy. 
Adherence to treatment was evaluated on the basis of the patient’s diary, which 
included the time of taking a fixed combination of antihypertensive drugs and BP levels in the 
morning and evening hours. In addition, in the diary, the patient entered the information on 
the number of steps taken during the day, which were measured using a pedometer.  
Physical examination of patients included measurements of height, body weight, and 
BMI calculation. Patients’ waist circumference (WC) and hip circumference (HC) were 
measured, and waist-to-hip ratio was calculated. Office BP was measured in accordance with 
the 2018 ESC/ESH Guidelines for the management of AH [1]. Pulse BP was evaluated as the 
difference between SBP and DBP. Average BP was calculated by the formula:  
Average BP = 0.42 x (SBP – DBP) + DBP. 
Lipid metabolism was assessed by total cholesterol, triglycerides, LDL and HDL 
cholesterol. Carbohydrate metabolism was assessed by blood glucose, HbA1c and insulin 
levels. Insulin resistance (IR) was determined by the HOMA model. The activity of the renin–
angiotensin–aldosterone system (RAAS) was evaluated by the levels of aldosterone and renin 
plasma, as well as by the aldosterone-renin ratio (ARR). The inflammatory activity was 
evaluated by the levels of interleukin 6 (IL-6) and C-reactive protein (CRP). The functional 
state of adipose tissue was assessed by blood levels of leptin and adiponectin. The state of the 
prooxidant system was evaluated by the levels of molecular products of lipid peroxidation — 
diene conjugates (DC) and malonic dialdehyde (MDA), and the state of the antioxidant 
protection system — by the total antioxidant activity. 
Morphofunctional properties of the myocardium were evaluated during ultrasound 
examination of the heart in one-dimensional, two-dimensional and Doppler modes by 
conventional methods. The volumes of left and right atria (LA and RA, respectively), end-
systolic and end-diastolic diameters (ESD and EDD, respectively) of the left ventricle 
(LV), diameters of LA and aorta (LAD and AD, respectively) were evaluated. The 
ejection fraction (EF) was calculated by the formula:  
EF = (EDV – ESV) / EDV, 
where ESV and EDV are the end-systolic and end-diastolic LV volumes, 
respectively. 
The thickness of the posterior wall of the LV and the thickness of the 
interventricular septum in the systole (TPWs and TIVSs, respectively) and diastole (TPWd 
and TIVSd, respectively) were measured. The relative wall thickness of the LV (RWT) 
was calculated by the formula:  
RWT = (TPWd + TIVSd) / EDD.  
The LV myocardial mass index (MMILV) was calculated as the ratio of the LV 
myocardial mass (MMLV) to the surface area of the body (S):  
MMILV = MMLV / S. 
Left ventricular diastolic function was evaluated by pulmonary artery blood flow and 
transmitral diastolic blood flow in pulsed Doppler with the determination of the following 
parameters: maximum early LV filling rate in spectral mode (E), maximum late (atrial) filling 
speed (A), ratio of maximal rates of early and late filling of LV at spectral mode (E/A), time 
of isovolumic relaxation of LV (IVRT), time of deceleration early diastolic flow rate (DT), 
maximum early LV filling rate at tissue mode (e), mean pulmonary artery pressure (AP) by 
Kitabatake, ratio of E and e (E/e). 
The degree of EDVD was determined in the sample with reactive hyperemia. At the 
same time, the intima-media thickness (IMT) in the carotid artery (CA) was measured 2 cm 
more proximal to the bifurcation of the common CA. The pulse wave velocity (PWV) in the 
CA was determined by the W-Track method; determination of the PWV in the abdominal 
aorta (AA) was performed using a phased sensor. 
The statistical processing of the obtained data was carried out using the package of 
statistical software “SPSS 17” (IBM), Microsoft Office Exel-2003. The data are presented as 
mean values ± standard deviation. Significance was set at a p value of < 0.05 in all cases. 
 
Results 
The comparative assessment of patients’ values in the presence and absence of RH after 
6 months of therapy was first of all performed (Tab. 1). It was found that after 6 months of 
therapy, patients with RH had higher BMI and higher BP levels compared to patients without 
this condition.  
It should be noted that patients with RH also had more pronounced cardiovascular 
remodeling (higher IMT CA, IVS, TPW, TIVS LVM, E/e and lower EF), higher levels of 
triglycerides, insulin, HbA1c, more pronounced IR (which was confirmed by greater HOMA-
IR), greater imbalance of adipokines, proinflammatory activity and higher RAAS activity 
(Tab. 1). 
A comparative assessment of pseudo-resistance and true resistance showed that patients 
with true resistance differed from pseudo-resistant patients by having significantly lower BMI 
(p = 0.02) (Tab. 2). In addition, in the absence of differences in BP levels, cardiovascular 
remodeling, and lipid and carbohydrate profiles, patients with true resistance had significantly 
higher levels of aldosterone (p = 0.04), higher activity of oxidative stress (MDA, p = 0.01 and 
DC, p = 0.03), a lower level of total antioxidant protection (p = 0.00), a higher level of 
adiponectin (p = 0.00), and a lower level of leptin (p = 0.00), compared with pseudo-resistant 
patients. 
 
Discussion 
The literature suggests that between 50% and 80% of patients with AH who are 
prescribed antihypertensive drugs show suboptimal adherence to treatment. In many cases, 
this high percentage of failure to reach target BP levels is at least in part due to the large 
number of drugs, the complexity of their dosage, the high incidence of adverse reactions, poor 
patient-physician relationships, and the inertia of the clinician with reduced adherence to 
treatment [2, 10]. 
Renin–angiotensin–aldosterone system plays a key role in the BP regulation, and its 
excessive activity is responsible for a wide range of side effects in the cardiovascular system, 
which, due to the increased concentration of angiotensin II and aldosterone, lead to an 
increase in BP, an increase in extracellular fluid volume, activation of hypercoagulation, and 
acceleration of fibrosis processes in the heart and vessels [11–14]. 
It is known that most obese individuals have a high level of blood aldosterone, and as 
the obesity progresses, the concentration of this hormone increases. A number of studies have 
found a clear correlation between aldosterone levels and BMI. The results of a large 
Framingham Offspring Study show a direct relationship between elevated plasma aldosterone 
levels and high BP in 1688 patients [15]. It is possible that secondary hyperaldosteronism 
accompanying obesity also contributes greatly to the development of AH in these patients. 
This relationship is well observed in studies on the reduction of excess body weight, where 
weight loss entails a decrease in the concentration of aldosterone in the blood and is 
accompanied by a decrease in BP [5, 9, 13]. 
Aldosterone has also been shown to adversely affect carbohydrate metabolism through 
three major mechanisms: IR, reduced insulin production, and activation of gluconeogenesis 
[3, 6, 9, 12]. 
The data obtained in our work show that patients with resistant hypertension differed 
from non-resistant patients with more pronounced cardiovascular remodeling, IR and 
metabolic disorders; it can be explained by the negative effect of aldosterone, which levels are 
significantly higher in RH. 
Significantly lower BMI in patients with true resistance could be explained by their 
sufficient physical activity, whereas pseudo-resistant patients in our study did not follow the 
physician's recommendations for providing adequate levels of physical activity. That is why, 
in the absence of a difference in BMI values between true resistant and pseudo-resistant 
patients at the beginning of the study, patients with true RH after complex 6-month therapy 
(including increased physical activity) had significantly lower BMI than pseudo-resistant 
ones. Higher adiponectin levels and lower leptin levels with true resistance can be explained 
by a large decrease in body weight of these patients compared to pseudo-resistant ones. It is 
known that in lower body weight, adiponectin is higher and leptin is lower than in higher 
body weight. The more pronounced imbalance of the system of oxidative stress-antioxidant 
protection in patients with true RH can be explained by significantly higher levels of 
aldosterone, compared to pseudo-resistant patients. 
 
Limitations of the study 
Our study included only patients of a certain age group (45–55 years old). Perhaps in 
other age groups (or a wider age range) hemodynamic and metabolic parameters with true and 
pseudo-resistant AH would have different features. A limitation of our work is also that 
adherence to the therapy of our patients was evaluated according to their diaries, which may 
be somewhat subjective. In addition, when evaluating the effectiveness of antihypertensive 
therapy, we took into account the data of office and home BP monitoring, but did not perform 
ambulatory BP monitoring, which is a more sensitive method for identifying masked 
uncontrolled hypertension. 
 
Conclusions 
Thus, in our work it was found that patients with resistant hypertension differed from 
hypertensive obese patients without resistance by having higher BMI and BP, higher levels of 
triglycerides, insulin, HbA1c, more pronounced IR, cardiovascular remodeling, imbalance of 
oxidative stress-antioxidant protection system, higher proinflammatory and RAAS activity. 
Patients with true resistance differed from pseudo-resistant patients by having significantly 
lower BMI, higher aldosterone levels more pronounced imbalance of the system of oxidative 
stress-antioxidant protection and less pronounced adipokines imbalance. 
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Table 1. Comparative assessment of indicators in patients 6 months after treatment, 
depending on the presence of resistant arterial hypertension (AH) 
Indicators 
Resistant AH is absent 
(n = 152) 
Resistant AH is present 
(n = 48) 
р 
Weight [kg] 92.62 ± 9.65 98.56 ± 7.51 0.00 
BMI [kg/m2] 31.85 ± 2.53 34.44 ± 1.37 0.00 
Waist [cm] 99.13 ± 6.79 101.65 ± 6.35 0.02 
Hip [cm] 108.38 ± 10.39 105.52 ± 5.54 0.07 
Waist-to-hip ratio 0.96 ± 0.60 0.97 ± 0.08 0.97 
SBP [mm Hg] 136.34 ± 1.83 138.05 ± 1.43 0.00 
DBP [mm Hg] 86.43 ± 1.01 88.23 ± 0.75 0.00 
Pulse BP [mm Hg] 48.90 ± 2.03 49.13 ± 1.62 0.49 
Average BP [mm Hg] 103.87 ± 0.88 105.86 ± 0.92 0.00 
Heart rate [bpm] 68.89 ± 3.22 68.83 ± 3.70 0.92 
IMT CA [mm] 0.87 ± 0.08 0.93 ± 0.08 0.00 
IMT CA bifurcation 
[mm] 
1.26 ± 0.15 1.29 ± 0.13 0.19 
PWV CA [m/s] 7.84 ± 1.04 7.82 ± 0.99 0.90 
PWV AA [m/s] 7.75 ± 1.03 7.80 ± 1.00 0.75 
EDVD (%) 7.89 ± 1.29 7.92 ± 0.91 0.86 
Total cholesterol 
[mmol/L] 
5.72 ± 0.47 5.79 ± 0.38 0.31 
Triglycerides [mmol/L] 1.70 ± 0.28 1.95 ± 0.42 0.00 
LDL cholesterol 
[mmol/L] 
4.56 ± 0.47 4.72 ± 0.45 0.08 
HDL cholesterol, 
[mmol/L] 
1.04 ± 0.13 1.03 ± 0.19 0.37 
Glucose [mmol/L] 4.66 ± 0.30 4.69 ± 0.29 0.49 
Insulin [μU/mL] 11.19 ± 4.02 16.36 ± 2.80 0.00 
НОМА-IR 2.32 ± 0.85 3.39 ± 0.60 0.00 
HbA1c (%) 4.68 ± 0.30 4.82 ± 0.32 0.02 
Total antioxidant 
activity [mmol/L] 
1.26 ± 0.06 1.18 ± 0.06 0.00 
MDA [nmol/mL] 30.38 ± 2.53 32.80 ± 1.72 0.00 
DC [nmol/mL] 27.09 ± 3.57 31.08 ± 3.45 0.00 
IL-6 [ng/mL] 106.75 ± 6.94 109.82 ± 7.53 0.01 
CRP [ng/mL] 4.26 ± 0.75 4.51 ± 0.72 0.04 
Aldosteron [ng/dl] 14.27 ± 1.62 14.76 ± 1.32 0.32 
Renin, ng/ml/hour 2.19 ± 0.46 2.53 ± 0.47 0.01 
АRR 7.60 ± 1.56 6.11 ± 1.54 0.00 
Adiponectin [ng/mL] 7.49 ± 1.06 8.09 ± 0.98 0.00 
Leptin [ng/mL] 11.61 ± 2.20 12.73 ± 2.03 0.00 
IVSd [sm] 1.10 ± 0.12 1.15 ± 0.11 0.01 
IVSs [sm] 1.30 ± 0.14 1.36 ± 0.13 0.01 
TPWd [sm] 1.09 ± 0.13 1.14 ± 0.14 0.02 
TPWs [sm] 1.51 ± 0.33 1.55 ± 0.36 0.53 
TIVSd [sm] 4.98 ± 0.32 5.04 ± 0.41 0.30 
TIVSs [sm] 3.12 ± 0.25 3.20 ± 0.30 0.04 
EF (%) 67.13 ± 3.20 65.86 ± 2.24 0.01 
LVM [g] 244.72 ± 60.55 267.79 ± 73.88 0.03 
LVMMI [g/m2] 120.00 ± 29.06 128.69 ± 35.85 0.09 
RWT 0.44 ± 0.04 0.46 ± 0.04 0.01 
LAD [mm] 37.33 ± 3.03 37.29 ± 3.54 0.95 
AD [mm] 32.47 ± 1.60 32.07 ± 0.59 0.09 
Mean pulmonary AP 
[mm Hg] 
15.54 ± 3.12 15.71± 2.97 0.75 
RAV [mL] 38.31 ± 4.90 37.40 ± 3.81 0.24 
LAV [mL] 46.71 ± 4.64 48.31 ± 4.09 0.03 
E [cm/s] 69.91 ± 11.68 67.49 ± 6.18 0.17 
A [cm/s] 78.99 ± 11.11 77.67 ± 8.05 0.46 
E/A 0.94 ± 0.19 0.90 ± 0.09 0.19 
DT [s] 0.15 ± 0.09 0.15 ± 0.09 0.96 
IVRT [s] 0.10 ± 0.02 0.11 ± 0.02 0.11 
Е [cm/s]  12.61 ± 2.54 11.57 ± 2.28 0.01 
E/e  5.67 ± 1.04 6.04 ± 1.25 0.04 
A — maximum late (atrial) filling speed; AA — aortic arch; AP — artery pressure; ARR — 
aldosterone-renin ratio; BMI — body mass index; BP — blood pressure; CA — carotid artery; CRP 
— C-reactive protein; DBP — diastolic blood pressure; DC — diene conjugates; DT — time of 
deceleration early diastolic flow rate; E — filling rate in spectral mode; e — maximum early LV 
filling rate at tissue mode; E/A — ratio of maximal rates of early and late filling of LV at spectral 
mode; E/e — ratio of E and e; EDVD —  endothelium-dependent vasodilatation; EF — ejection 
fraction; HbA1c — glycated hemoglobin; HDL — high density lipoprotein; IL-6 — interleukin 6; 
HOMA-IR — Homeostatic Model Assessment for Insulin Resistance; IMT — intima-media thickness; 
IVRT — time of isovolumic relaxation of LV; IVSd, interventricular septum (diastole); IVSs, 
interventricular septum (systole); LDL — low-density lipoprotein; LVM — left ventricular mass; 
MDA — malonic dialdehyde; RAV — right atrial volume; LAV — left atrial volume; SBP — systolic 
blood pressure; PWV — pulse wave velocity; TIVSd – thickness of the interventricular septum 
(diastole); TIVSs – thickness of the interventricular septum (systole); TPWd — thickness of the 
posterior wall of the left ventricle in diastole; TIVSd — the thickness of the interventricular septum in 
diastole 
 
Table 2. Comparison of patients with pseudo-resistant and true resistant arterial hypertension 
(AH) 
Indicators Pseudo-resistant AH True resistant AH р 
(n = 27) (n = 21) 
Weight [kg] 99.56 ± 8.37 97.29 ± 6.21 0.43 
BMI [kg/m2] 34.83 ± 1.28 33.93 ± 1.35 0.02 
Waist [cm] 101.56 ± 6.73 101.76 ± 6.00 0.91 
Hip [cm] 105.26 ± 5.40 105.86 ± 5.82 0.79 
Waist-to-hip ratio 0.97 ± 0.08 0.96 ± 0.08 0.95 
SBP [mm Hg] 137.30 ± 1.52 137.43 ± 1.48 0.71 
DBP [mm Hg] 88.25 ± 0.82 88.41 ± 0.84 0.93 
Pulse BP [mm Hg] 49.07 ± 1.62 49.19 ± 1.66 0.76 
Average BP [mm Hg] 104.03 ± 0.96 104.92 ± 0.79 0.88 
Heart rate [bpm] 68.78 ± 4.47 68.90 ± 2.51 0.47 
IMT CA [mm] 0.94 ± 0.08 0.92 ± 0.08 0.41 
IMT CA bifurcation 
[mm] 
1.31 ± 0.12 1.29 ± 0.14 0.06 
PWV CA [m/s] 8.06 ± 1.08 7.51 ± 0.79 0.06 
PWV AA [m/s] 8.00 ± 0.92 7.55 ± 1.06 0.24 
EDVD (%) 7.84 ± 1.01 8.02 ± 0.77 0.25 
Total cholesterol 
[mmol/L] 
5.83 ± 0.40 5.75 ± 0.36 0.35 
Triglycerides [mmol/L] 1.77 ± 0.33 1.61 ± 0.14 0.07 
LDL cholesterol 
[mmol/L] 
4.69 ± 0.49 4.77 ± 0.40 0.72 
HDL cholesterol 
[mmol/L] 
1.03 ± 0.10 1.04 ± 0.09 0.09 
Glucose [mmol/L] 4.70 ± 0.32 4.61 ± 0.26 0.18 
Insulin [μU/mL] 16.01 ± 2.61 16.80 ± 3.03 0.28 
НОМА-IR 3.34 ± 0.57 3.44 ± 0.64 0.44 
HbA1c (%) 4.65 ± 0.33 4.71 ± 0.27 0.17 
Total antioxidant 
activity [mmol/L] 
1.22 ± 0.05 1.16 ± 0.05 0.00 
MDA [nmol/mL] 32.24 ± 1.53 33.24 ± 1.76 0.01 
DC [nmol/mL] 32.54 ± 2.78 29.95 ± 3.54 0.03 
IL-6 [ng/mL] 109.55 ± 7.44 111.91 ± 8.31 0.06 
CRP [ng/mL] 4.32 ± 0.61 4.66 ± 0.77 0.17 
Aldosteron [ng/dL] 14.34 ± 1.23 15.09 ± 1.31 0.04 
Renin [ng/mL/hour] 2.57 ± 0.44 2.50 ± 0.50 0.86 
АRR 5.80 ± 1.38 6.35 ± 1.64 0.23 
Adiponectin [ng/mL] 7.44 ± 0.64 8.93 ± 0.67 0.00 
Leptin [ng/mL] 13.72 ± 1.93 11.46 ± 1.34 0.00 
IVSd [sm] 1.15 ± 0.09 1.16 ± 0.13 0.64 
IVSs [sm] 1.37 ± 0.13 1.34 ± 0.14 0.36 
TPWd [sm] 1.14 ± 0.12 1.15 ± 0.17 0.15 
TPWs [sm] 1.51 ± 0.28 1.60 ± 0.44 0.70 
TIVSd [sm] 5.01 ± 0.35 5.07 ± 0.48 0.78 
TIVSs [sm] 3.19 ± 0.27 3.22 ± 0.34 0.63 
EF (%) 65.82 ± 1.82 65.90 ± 2.74 0.33 
LVM [g] 262.76 ± 57.30 274.26 ± 92.09 0.45 
LVMMI [g/m2] 126.05 ± 29.86 132.08 ± 42.89 0.72 
RWT 0.46 ± 0.04 0.46 ± 0.04 0.91 
LAD [mm] 37.38 ± 3.65 37.19 ± 3.47 0.21 
AD [mm] 31.98 ± 0.68 32.18 ± 0.44 0.01 
Mean pulmonary AP 
[mm Hg] 
15.75 ± 3.06 15.64 ± 2.93 0.29 
RAV [mL] 37.14 ± 3.71 37.73 ± 4.00 0.61 
LAV [mL] 48.42 ± 4.46 48.18 ± 3.67 0.80 
E [cm/s] 66.09 ± 6.70 69.28 ± 5.04 0.07 
A [cm/s] 75.83 ± 7.33 73.94 ± 8.25 0.26 
E/A 0.89 ± 0.12 0.91 ± 0.10 0.05 
DT [s] 0.16 ± 0.12 0.13 ± 0.03 0.11 
IVRT [s] 0.11 ± 0.02 0.12 ± 0.03 0.07 
е [cm/s]  11.33 ± 2.03 11.87 ± 2.58 0.47 
Е/е 6.00 ± 1.15 6.10 ± 1.39 0.86 
For the abbreviations see Table 1. 
